"Around this same time, MannKind’s Afrezza, an inhalable form of insulin, was denied approval by the FDA as well. Without additional clinical studies and at least one trial comparing the new inhaler with an earlier version, Afrezza will never hit the market.

Furthermore, Afrezza wasn’t the only diabetic medication whose market potential was rightfully stunted by the FDA in the last year. AstraZeneca and Bristol-Myers Squibb’s drug dapagliflozin was denied approval because of significant concerns about breast and bladder cancers seen in patients taking the drug."

http://chicago-land.injuryboard.com/fda-and-prescription-drugs/a-future-of-doubt-for-diabetes-sufferers-history-forces-us-to-question-the-future.aspx?googleid=301626